CNN2 Antibody

What is CNN2 and why is it important in scientific research?

CNN2, also known as Calponin 2 or neutral calponin, is an actin cytoskeleton-associated regulatory protein that inhibits myosin-ATPase activity and regulates cytoskeleton dynamics. It is essential for the contraction of smooth muscle cells, playing a key role in vascular tone regulation and smooth muscle cell migration . CNN2 predominantly expresses in smooth muscle tissues and various non-muscle cells where it influences cellular tension and mechanical processes .

The significance of CNN2 in research stems from its involvement in:

• Smooth muscle contraction mechanisms

• Cell migration and invasion processes

• Cancer progression, particularly in hepatocellular carcinoma (HCC) and colorectal cancer

• Inflammatory response regulation in macrophages

Research has demonstrated that dysregulation of CNN2 is implicated in diseases such as hypertension, cardiovascular disorders, and various cancers, making it a promising target for therapeutic intervention .

What are the validated applications for CNN2 antibodies in laboratory research?

CNN2 antibodies have been validated for multiple experimental applications, with specific uses dependent on the antibody clone and manufacturer. Based on the search results, the primary validated applications include:

Most CNN2 antibodies show reactivity with human samples, and many also cross-react with mouse and rat samples due to sequence homology . For optimal results, researchers should perform validation testing on their specific sample types and experimental conditions, as reactivity can vary between antibody clones .

How should I select an appropriate CNN2 antibody for my specific research needs?

When selecting a CNN2 antibody, consider these critical factors:

• Immunogen specificity: Review whether the antibody was raised against the specific region of CNN2 relevant to your research. For example, some antibodies target the N-terminal region (AA 9-36), while others target internal regions (AA 101-200) or the C-terminus .

• Clonality:

  • Polyclonal antibodies (like PACO48726) offer broader epitope recognition but may have batch-to-batch variation

  • Monoclonal antibodies provide consistent specificity but might recognize only a single epitope

• Validated applications: Ensure the antibody has been validated for your specific application (WB, IHC, IF, etc.) with published examples .

• Species reactivity: Confirm cross-reactivity with your experimental species. Many CNN2 antibodies react with human and mouse samples, but cross-reactivity with other species varies .

• Publication record: Search for antibodies that have been successfully used in published research similar to your experimental approach .

For researchers studying CNN2 in cancer contexts, antibodies validated specifically in cancer tissues may be preferable. Similarly, for inflammatory studies, consider antibodies validated in immune cell populations .

How does CNN2 contribute to cancer metastasis mechanisms?

CNN2 has been identified as a significant factor in cancer metastasis through several mechanisms:

• Regulation of cell migration and invasion: Research demonstrates that CNN2 is implicated in the migration and invasion of liver cancer cells. Downregulation of CNN2 inhibits migration and invasion capabilities of these cells, suggesting a direct role in metastatic processes .

• HCC association: CNN2 is recognized as a newly identified HCC-associated antigen. The presence of CNN2 antibodies in patient serum shows significantly higher positive rates in HCC patients (54.8%) compared to other cancers and normal tissues, suggesting specificity to liver cancer pathology .

• Colorectal cancer progression: Studies indicate that CNN2 is highly expressed in colon cancer tissues compared to paired normal tissues. Experimental evidence shows that:

  • CNN2 protein levels are elevated in multiple cancer cell lines compared to normal colon tissue (HIEC)

  • CNN2 silencing significantly inhibits colorectal cancer cell proliferation and enhances apoptosis

  • Knockdown of CNN2 expression in CRC cells resulted in 523 up-regulated genes and 648 down-regulated genes, suggesting complex downstream effects

• EGR1-dependent signaling pathway: Research has identified EGR1 as a potential downstream target of CNN2 in colorectal cancer. CNN2 silencing experiments revealed that EGR1 was down-regulated, and analysis of TCGA database showed co-expression profiles between CNN2 and EGR1 .

These findings collectively position CNN2 as a potential therapeutic target for cancer treatment. Researchers investigating CNN2's role in metastasis should consider monitoring both CNN2 expression and downstream targets like EGR1 in their experimental designs .

What methodological approaches are recommended for studying CNN2 in macrophage populations?

CNN2 expression in macrophages varies depending on tissue location, correlating with their functional state and adaptation to specific microenvironments. For researchers studying CNN2 in macrophages, these methodological approaches are recommended:

• Comparative expression analysis:

  • Research has shown that lung resident macrophages express significantly lower calponin 2 than peritoneal resident macrophages, correlating with decreased substrate adhesion and reduced proinflammatory cytokine expression

  • When designing experiments, include multiple macrophage populations to capture tissue-specific differences

• Knockout/knockdown approaches:

  • Generate Cnn2−/− macrophage models to study functional consequences

  • Research demonstrates that deletion of calponin 2 in peritoneal macrophages decreases substrate adhesion and downregulates proinflammatory cytokine expression

  • For conditional studies, consider shRNA approaches (as used in CNN2 cancer studies )

• Substrate adhesion assays:

  • Measure changes in macrophage adhesion properties as this correlates with CNN2 expression

  • Analyze both static and dynamic adhesion under different inflammatory stimulation conditions

• Cytokine profiling:

  • Assess proinflammatory and anti-inflammatory cytokine expression profiles

  • Research indicates that CNN2 levels correlate with inflammatory activation states

• Mechanical adaptation studies:

  • Evaluate how CNN2 contributes to macrophage adaptation in mechanically dynamic tissue microenvironments

  • Consider endoplasmic reticulum stress markers as possible mechanisms for CNN2-mediated regulation of cytokine processing and secretion

When designing experiments, researchers should account for the cytoskeleton-based mechanisms by which CNN2 may alter the processing and secretion of cytokines, potentially via endoplasmic reticulum stress pathways .

How can CNN2 be effectively used as a biomarker in hepatocellular carcinoma diagnosis?

Research indicates that CNN2 has diagnostic potential as a biomarker for hepatocellular carcinoma (HCC), particularly when combined with existing markers. The methodological approach for utilizing CNN2 as a biomarker includes:

This approach has particular value for detecting early-stage and small HCC, where traditional markers like AFP have limited sensitivity. The combination of CNN2 with other HCC-related factors represents a promising strategy for improving early detection capabilities .

What are the optimal protocols for using CNN2 antibodies in Western blot applications?

For optimal Western blot results with CNN2 antibodies, researchers should follow these methodological guidelines:

• Sample preparation:

  • Prepare cell lysates in RIPA buffer (as used successfully with HepG2 lysates)

  • Recommended protein loading: 30-35 μg per lane

  • Include positive control samples: HeLa, HepG2, and mouse liver/lung tissues have shown consistent CNN2 expression

• Electrophoresis and transfer:

  • Use standard SDS-PAGE separation (10-12% gels appropriate for CNN2's 34 kDa size)

  • Transfer to PVDF or nitrocellulose membranes using standard protocols

• Antibody dilutions and incubation:

  • Primary antibody dilution ranges:

    • Polyclonal antibodies: 1:500-1:5000

    • Monoclonal antibodies: 1:2000-1:10000

  • For Abcam's ab129331: optimal concentration is 0.03 μg/mL

  • Incubation: Overnight at 4°C or 1-2 hours at room temperature

• Detection systems:

  • ECL-based detection systems have been validated for CNN2 antibodies

  • Secondary antibody recommendations:

    • For rabbit primary: Goat anti-rabbit IgG-HRP (1:50000 dilution)

    • For mouse primary: Anti-mouse IgG-HRP (dilution per manufacturer)

• Expected results and interpretation:

  • Predicted band size: 34 kDa

  • Observed molecular weight range: 34-36 kDa

  • Multiple bands may indicate isoforms, phosphorylation states, or degradation products

  • Positive controls will help distinguish specific from non-specific bands

• Validation controls:

  • Negative controls: CNN2 knockdown/knockout samples when available

  • Blocking peptide competition assays can confirm antibody specificity

  • Consider using two different CNN2 antibodies recognizing different epitopes for validation

These protocols have been validated in published research and commercial antibody documentation. Researchers should optimize conditions based on their specific experimental system and antibody source .

How can I optimize immunohistochemistry protocols for CNN2 detection in different tissue types?

Optimizing immunohistochemistry (IHC) for CNN2 detection requires careful consideration of tissue type and preparation methods. Based on validated protocols in the literature:

• Tissue preparation and antigen retrieval:

  • Formalin-fixed, paraffin-embedded (FFPE) sections (4-6 μm thickness) are commonly used

  • Critical step: Antigen retrieval method significantly impacts results:

    • Primary recommendation: TE buffer pH 9.0

    • Alternative: Citrate buffer pH 6.0

    • Heat-induced epitope retrieval (pressure cooker or microwave) is typically required

• Blocking and antibody concentrations:

  • Block with 5-10% normal serum (matching secondary antibody host)

  • Antibody dilution ranges:

    • For polyclonal antibodies: 1:20-1:200

    • For monoclonal antibodies: 5-20 μg/mL

  • Primary incubation: 1-2 hours at room temperature or overnight at 4°C

• Tissue-specific considerations:

  • Smooth muscle tissues: Lower antibody concentrations (1:100-1:200) as CNN2 expression is typically high

  • Cancer tissues: May require higher antibody concentrations (1:20-1:50) for optimal detection

  • Normal tissues: Include adjacent normal tissue as internal control when possible

• Detection systems:

  • DAB-based detection is standard for brightfield microscopy

  • For fluorescent detection, tyramide signal amplification can enhance sensitivity

• Validated positive control tissues:

  • Human placenta has been validated for CNN2 antibody testing

  • Human heart tissue and hysteromyoma tissue also show reliable CNN2 expression

  • HCC tissues show heightened CNN2 expression compared to adjacent normal liver

• Quantification approaches:

  • Semi-quantitative scoring (0-3+) of staining intensity

  • H-score method (intensity × percentage of positive cells)

  • Digital image analysis using specialized software

• Common pitfalls and solutions:

  • High background: Increase blocking time/concentration or reduce antibody concentration

  • Weak signal: Optimize antigen retrieval and consider signal amplification methods

  • Non-specific staining: Include isotype control and absorption controls

For researchers studying CNN2 in cancer contexts, comparing CNN2 expression between tumor tissue and adjacent normal tissue within the same section can provide valuable internal controls .

What considerations are important when designing CNN2 knockdown or knockout experiments?

Designing effective CNN2 knockdown/knockout experiments requires careful attention to experimental design and validation. Based on successful approaches in the literature:

• Selection of knockdown/knockout method:

  • shRNA approach: The literature demonstrates successful CNN2 knockdown using shRNA in colorectal cancer cells (HCT116 and RKO)

    • Multiple shRNA constructs should be tested (shCNN2-2 and shCNN2-3 showed highest efficiency)

    • Include appropriate non-targeting shRNA controls (shCtrl)

  • CRISPR-Cas9 knockout: For complete gene deletion studies

    • Target early exons to ensure complete protein disruption

    • Design multiple guide RNAs to improve targeting efficiency

    • Consider potential off-target effects

• Validation of knockdown/knockout efficiency:

  • mRNA level: Quantitative RT-PCR to measure CNN2 transcript levels

  • Protein level: Western blotting using validated CNN2 antibodies

  • Expected reduction: Aim for >70% reduction in expression for meaningful functional studies

  • Verification methods: Both fluorescence imaging and protein/mRNA quantification should be used to confirm knockdown success

• Functional assays to assess phenotypic effects:

  • Cell proliferation: Proven to be significantly inhibited after CNN2 knockdown in CRC cells

  • Apoptosis: Flow cytometry has shown enhanced cell apoptosis following CNN2 knockdown

  • Migration/invasion assays: Critical for assessing CNN2's role in metastatic potential

  • Cytoskeletal organization: Immunofluorescence for actin filaments and focal adhesions

• Downstream analysis:

  • Gene expression changes: RNA-seq analysis revealed 523 up-regulated and 648 down-regulated genes following CNN2 knockdown in CRC cells

  • Pathway analysis: Ingenuity Pathway Analysis identified CNN2-centered molecular interaction networks

  • Identification of key targets: EGR1 was identified as a downstream target of CNN2 in CRC

• In vivo validation:

  • CNN2 knockdown effects observed in cell lines should be verified in animal models

  • Consider tissue-specific or inducible knockout systems for developmental studies

• Rescue experiments:

  • Re-express CNN2 in knockdown/knockout cells to confirm phenotype specificity

  • Consider expressing specific CNN2 domains to identify functional regions

When designing these experiments, researchers should consider the potential tissue-specific roles of CNN2, as its function varies between tissue types such as smooth muscle, cancer cells, and macrophages .

How can CNN2 antibodies be used to investigate the role of CNN2 in inflammatory responses?

CNN2 plays a significant role in regulating inflammatory responses, particularly in macrophages. Researchers can utilize CNN2 antibodies to investigate this relationship through several methodological approaches:

• Comparative expression analysis across macrophage populations:

  • Use CNN2 antibodies for Western blot and immunofluorescence to compare expression levels between:

    • Lung resident macrophages (which express lower CNN2)

    • Peritoneal resident macrophages (which express higher CNN2)

  • This approach reveals how CNN2 expression correlates with inflammatory phenotypes

• Temporal expression changes during inflammation:

  • Monitor CNN2 expression changes in macrophages following exposure to:

    • LPS or other TLR agonists

    • Pro-inflammatory cytokines (TNF-α, IL-1β)

    • Anti-inflammatory stimuli (IL-4, IL-10)

  • Use time-course experiments with CNN2 antibodies to track expression changes

• Co-localization studies with cytoskeletal components:

  • Perform dual immunofluorescence with CNN2 antibodies and markers for:

    • Actin filaments (phalloidin staining)

    • Myosin

    • Focal adhesion proteins

  • This reveals how CNN2 interacts with the cytoskeleton during inflammatory activation

• Correlation with inflammatory cytokine production:

  • Use CNN2 antibodies to sort cells based on CNN2 expression levels

  • Analyze cytokine production profiles in CNN2-high versus CNN2-low populations

  • Research indicates that lower CNN2 expression correlates with decreased proinflammatory cytokine expression

• Tissue-specific inflammation studies:

  • Apply CNN2 antibodies in immunohistochemistry of inflamed tissues

  • Compare CNN2 expression in resident versus infiltrating macrophages

  • Correlate with disease severity markers in models of inflammatory diseases

• Mechanistic investigations:

  • Immunoprecipitate CNN2 using specific antibodies to identify binding partners in inflammatory conditions

  • Analyze how CNN2-cytoskeleton interactions change during inflammatory activation

  • Investigate how CNN2 influences ER stress responses that may alter cytokine processing

Research has demonstrated that deletion of calponin 2 restricts proinflammatory activation of macrophages in atherosclerosis and arthritis, attenuating disease progression in mice . Using CNN2 antibodies to understand the molecular mechanisms behind this effect could lead to novel anti-inflammatory therapeutic strategies.

What are the recommended approaches for detecting CNN2 in patient samples for cancer biomarker studies?

For researchers conducting cancer biomarker studies involving CNN2, several methodological approaches have been validated for patient sample analysis:

• Serum autoantibody detection:

  • Indirect ELISA method:

    • Coat ELISA plates with purified CNN2 recombinant protein

    • Detect presence of CNN2 antibodies in patient serum

    • Establish cut-off values based on normal control sera (±3SD from normal mean)

    • This approach showed 21.14% sensitivity and 94.30% specificity for HCC

• SEREX technique (Serological Analysis of Recombinantly Expressed cDNA Clone):

  • A validated approach for identifying autoantibodies against tumor-associated antigens

  • Used successfully to identify CNN2 antibodies in HCC patient serum with 54.8% positive rate

  • Allows screening of large patient cohorts for autoantibody responses

  • Consider complementing with other methods due to technical complexity

• Tissue expression analysis:

  • RT-PCR for mRNA detection:

    • Analyze paired tumor-normal tissues from patients

    • Research shows higher CNN2 mRNA in cancer tissues compared to paired normal tissues

    • Include housekeeping genes (GAPDH, β-actin) as internal controls

  • Immunohistochemistry protocols:

    • FFPE tissue sections (4-5 μm thickness)

    • Antigen retrieval: TE buffer pH 9.0 recommended

    • CNN2 antibody dilutions: 1:20-1:200 depending on antibody source

    • Semi-quantitative scoring based on staining intensity and percentage of positive cells

• Combined biomarker approaches:

  • Research demonstrates significantly improved detection when combining CNN2 with AFP:

    • CNN2 alone: 21.85% detection rate

    • AFP alone: 59.66% detection rate

    • Combined CNN2+AFP: 71.43% detection rate

  • Particularly valuable for small HCC detection (75% detection rate for combined markers)

• Analysis of circulating tumor cells (CTCs):

  • Use CNN2 antibodies in immunomagnetic separation or flow cytometry

  • Evaluate CNN2 expression in CTCs as potential marker of metastatic potential

• Controls and validation:

  • Include diverse control groups: healthy donors, benign disease (cirrhosis, hepatitis), and other cancer types

  • Research showed CNN2 autoantibody specificity for HCC versus other cancers:

    • HCC: 54.8% positive

    • Gastric cancer: 6.5%

    • Lung cancer: 3.2%

    • Rectal cancer: 9.7%

These methods have been successfully employed in clinical research settings and offer complementary approaches for incorporating CNN2 into cancer biomarker panels, particularly for HCC and colorectal cancer studies .

How might CNN2 antibodies contribute to therapeutic development for cancer?

CNN2's emerging role in cancer progression suggests several promising directions for therapeutic development using CNN2 antibodies:

• Targeted inhibition of CNN2 function:

  • Research demonstrates that CNN2 knockdown inhibits colorectal cancer cell proliferation and enhances apoptosis

  • CNN2-neutralizing antibodies could potentially mimic this effect in vivo

  • Antibody-based approaches could target CNN2 in tumor microenvironments while sparing normal tissues

• Cancer diagnostic and monitoring applications:

  • CNN2 antibodies can help stratify patients for targeted therapies based on CNN2 expression levels

  • Research shows CNN2 expression correlates with metastatic potential in HCC:

    • CNN2 mRNA positive rates: 56.67% in HCC with metastasis vs. 41.67% in non-metastatic HCC

    • CNN2 protein positive rates: 63.33% in metastatic HCC vs. 37.5% in non-metastatic HCC

  • Monitoring CNN2 expression changes during treatment could provide early indicators of response

• Antibody-drug conjugates (ADCs):

  • CNN2 antibodies conjugated to cytotoxic agents could deliver targeted therapy to CNN2-expressing cancer cells

  • Research targeting the CNN2-EGR1 pathway shows promise:

    • EGR1 was identified as a downstream target of CNN2 in colorectal cancer

    • Dual targeting of this pathway could enhance therapeutic efficacy

• Combination therapy approaches:

  • CNN2 antibodies could sensitize cancer cells to standard chemotherapies

  • Targeting CNN2's role in cell migration and invasion might enhance the efficacy of anti-metastatic therapies

• Methodological considerations for therapeutic development:

  • Selection of appropriate CNN2 epitopes for targeting is critical

  • Antibodies against functional domains affecting cytoskeletal interactions may be most effective

  • Consider tissue penetration challenges and potential on-target/off-tumor effects

  • Validate therapeutic antibodies in patient-derived xenograft models

• Biomarker development for personalized medicine:

  • CNN2 antibody-based assays could identify patients most likely to benefit from CNN2-targeting therapies

  • Combined biomarker panels including CNN2 could improve patient stratification

The emerging research on CNN2's EGR1-dependent promotion role in cancer development suggests that targeting this pathway could be particularly promising for therapeutic development . As research progresses, CNN2 antibodies will likely play crucial roles both as research tools to further elucidate CNN2's functions and as potential therapeutic agents.

What are the technical challenges in developing high-specificity CNN2 antibodies for research applications?

Developing highly specific CNN2 antibodies presents several technical challenges that researchers should consider:

• Structural homology with other calponin family members:

  • CNN2 shares significant homology with CNN1 (Calponin 1) and CNN3 (Calponin 3)

  • This necessitates careful epitope selection to avoid cross-reactivity

  • Target unique regions of CNN2 not conserved in other calponin family members

  • Validate specificity against recombinant CNN1, CNN2, and CNN3 proteins

• Post-translational modifications:

  • CNN2 undergoes phosphorylation and other modifications that may alter epitope accessibility

  • Consider developing modification-specific antibodies to study CNN2 regulation

  • Antibodies recognizing different CNN2 functional states may yield different experimental results

• Species cross-reactivity considerations:

  • When developing antibodies for comparative studies across species:

    • Human and mouse CNN2 share high homology but have distinct regions

    • Current antibodies show variable cross-reactivity patterns:

      • Some react with human and mouse (PACO48726)

      • Others show broader reactivity including pig samples

    • Test cross-reactivity experimentally rather than relying solely on sequence alignment predictions

• Application-specific challenges:

  • For IHC applications: Antibodies must recognize fixed/denatured CNN2 epitopes

  • For IP applications: Antibodies must recognize native protein conformation

  • For flow cytometry: Consider accessibility of epitopes in intact cells

  • Developing antibodies that perform well across multiple applications requires extensive validation

• Validation methodologies:

  • Employ CNN2 knockout/knockdown samples as gold-standard negative controls

  • Use multiple antibodies targeting different CNN2 epitopes for cross-validation

  • Conduct peptide competition assays to confirm specificity

  • Perform mass spectrometry validation of immunoprecipitated proteins

• Production and purification challenges:

  • Maintain consistent antibody characteristics across production batches

  • For polyclonal antibodies, consider affinity purification against the immunizing peptide

  • For monoclonal antibodies, extensive screening may be required to identify optimal clones

• Reproducibility challenges:

  • Document all validation methods thoroughly

  • Provide detailed experimental protocols with antibody usage

  • Report batch/lot numbers in publications to facilitate reproducibility

Developing antibodies that can distinguish between CNN2's various cellular contexts (smooth muscle vs. cancer cells vs. immune cells) remains an ongoing challenge in the field and represents an important research direction .